Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Yoshiyuki Takahashi"'
Autor:
Rui Zhang, Juan Xiao, Yuan Sun, Sanfang Tu, Yuhua Li, Leping Zhang, Yifei Cheng, Song Xue, Yongping Zhang, Bin Wang, Huyong Zheng, Nobuhiro Nishio, Yoshiyuki Takahashi, Seiji Kojima, Yingying Wang, Biljana Horn, Lung-Ji Chang
Publikováno v:
Frontiers in Hematology, Vol 2 (2023)
IntroductionAllogeneic hematopoietic stem cell transplantation (allo-HCT) is a standard treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However, about 30-40% of patients still relapse after HCT. Chimeric antigen rec
Externí odkaz:
https://doaj.org/article/174eecda57594ec196b5b82d0c79159f
Autor:
Mulita Sanyanusin, Suparat Tudsamran, Rattapoom Thaiwong, Supannikar Tawinwung, Nobuhiro Nishio, Yoshiyuki Takahashi, Nattiya Hirankarn, Koramit Suppipat
Publikováno v:
Cytotherapy. 25:397-406
Chimeric antigen receptor (CAR) T cell is a novel therapy for relapse and refractory hematologic malignancy. Characteristics of CAR T cells are associated with clinical efficacy and toxicity. The type of serum supplements used during cultivation affe
Autor:
Koji Kawaguchi, Katsutsugu Umeda, Satoshi Miyamoto, Nao Yoshida, Hiromasa Yabe, Takashi Koike, Michiko Kajiwara, Hiroshi Kawaguchi, Yoshiyuki Takahashi, Masataka Ishimura, Hirotoshi Sakaguchi, Asahito Hama, Yuko Cho, Maho Sato, Keisuke Kato, Atsushi Sato, Koji Kato, Ken Tabuchi, Yoshiko Atsuta, Kohsuke Imai
Publikováno v:
Bone Marrow Transplantation. 58:600-602
Autor:
Hiroyuki Shimada, Akihiko Tanizawa, Takeshi Kondo, Tokiko Nagamura-Inoue, Masahiro Yasui, Arinobu Tojo, Hideki Muramatsu, Tetsuya Eto, Noriko Doki, Masatsugu Tanaka, Maho Sato, Maiko Noguchi, Naoyuki Uchida, Yoshiyuki Takahashi, Naoki Sakata, Tatsuo Ichinohe, Yoshiko Hashii, Koji Kato, Yoshiko Atsuta, Kazuteru Ohashi
Publikováno v:
Transplantation and Cellular Therapy. 28:376-389
The breakthrough effects of tyrosine kinase inhibitors (TKIs) have lessened indications for allogeneic hematopoietic stem cell transplantation (HSCT) in chronic myeloid leukemia (CML). However, HSCT is still attractive for children and adolescents/yo
Autor:
Ryo Maemura, Manabu Wakamatsu, Kana Matsumoto, Hirotoshi Sakaguchi, Nao Yoshida, Asahito Hama, Taro Yoshida, Shunsuke Miwata, Hironobu Kitazawa, Kotaro Narita, Shinsuke Kataoka, Daisuke Ichikawa, Motoharu Hamada, Rieko Taniguchi, Kyogo Suzuki, Nozomu Kawashima, Eri Nishikawa, Atsushi Narita, Yusuke Okuno, Nobuhiro Nishio, Koji Kato, Seiji Kojima, Kunihiko Morita, Hideki Muramatsu, Yoshiyuki Takahashi
Publikováno v:
Cell transplantation. 31
Melphalan is widely used for hematopoietic stem cell transplantation (HSCT) conditioning. However, the relationship between its pharmacokinetic (PK) and transplantation outcomes in children has not been thoroughly investigated. We prospectively analy
Autor:
Maho Sato, Tomohiro Morio, Hiromasa Yabe, Akira Nishimura, Koji Kato, Yoshiyuki Takahashi, Masami Inoue, Satoshi Miyamoto, Takashi Koike, Akihiro Iguchi, Kohsuke Imai, Tomonari Shigemura, Yoshiko Atsuta, Yoji Sasahara, Michiko Kajiwara, Masakatsu Yanagimachi, Motohiro Kato, Yoshiko Hashii, Mio Kurata, Masataka Ishimura, Katsutsugu Umeda
Publikováno v:
Journal of Clinical Immunology
Purpose Hematopoietic cell transplantation (HCT) is a curative therapy for patients with severe combined immunodeficiency (SCID). Here, we conducted a nationwide study to assess the outcome of SCID patients after HCT in Japan. Methods A cohort of 181
Autor:
Hideki Muramatsu, Takashi Hashimoto, Yoshiyuki Takahashi, Yoshinao Muro, Seiji Kojima, Eri Nishikawa, Atsunari Tsuchisaka, Yusuke Okuno, Nozomu Kawashima, Atsushi Narita, Motoharu Hamada, Nobuhiro Nishio, Daisuke Ichikawa
Publikováno v:
Bone Marrow Transplantation. 56:2291-2294
Autor:
Yuichi Ishikawa, Tatsunori Goto, Katsuyoshi Kato, Tetsuya Nishida, Yoshiyuki Takahashi, Sonoko Kamoshita, Seitaro Terakura, Akihiro Hirakawa, Hitoshi Kiyoi, Nobuhiro Nishio, Satoshi Nishiwaki, Yoko Ushijima, Makoto Murata, Yoshiya Adachi, Tadashi Matsushita, Yoshihisa Kodera, Satoshi Suzuki
Publikováno v:
Stem Cells Translational Medicine
Stem Cells Translational Medicine, Vol 10, Iss 4, Pp 542-553 (2021)
Stem Cells Translational Medicine, Vol 10, Iss 4, Pp 542-553 (2021)
Mesenchymal stem cells (MSCs) have immunomodulatory properties and support hematopoiesis in the bone marrow (BM). To develop a new strategy to not only prevent graft‐vs‐host disease (GVHD) but also to enhance engraftment, a phase I trial of cord
Autor:
Toshiki Nakane, Tomohiko Nakata, Yu Okai, Hisashi Kawai, Masaharu Tanaka, Hiroyuki Kidokoro, Yoko Sakaguchi, Yoshiyuki Takahashi, Toshiaki Taoka, Jun Natsume, Hiroyuki Yamamoto, Yuji Ito, Hideki Muramatsu, Atsuko Ohno, Shinji Naganawa
Publikováno v:
Pediatric Neurology. 111:78-84
Background Advances in hematopoietic stem cell transplantation have improved the survival rate of malignant diseases and congenital immunodeficiencies. It has become important to assess long-term complications in survivors. To assess neurological abn
Autor:
Masaki Yamamoto, Satoru Miyano, Hideki Muramatsu, Seishi Ogawa, Hitoshi Kanno, Yuki Yuza, Yoji Sasahara, Etsuro Ito, Seiji Kojima, Hiromasa Yabe, Nobuyuki Hyakuna, Shouichi Ohga, Daiichiro Hasegawa, Kenichi Yoshida, Masanori Nishi, Takuya Kamio, Takeo Sarashina, Harumi Kakuda, Akira Ishiguro, Yoshiyuki Takahashi, Kiminori Terui, Tomohiko Sato, Tsutomu Toki, Akie Kobayashi, Masataka Ishimura, Rika Kanezaki, Hidefumi Hiramatsu, Akira Ohara, Miyuki Tanaka, Shinya Sasaki, Ko Kudo, Shun Koyamaishi
Publikováno v:
Bone Marrow Transplantation. 56:1013-1020
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of Diamond–Blackfan anemia (DBA). However, data regarding the optimal conditioning regimen for DBA patients are limited. We re